EGFR基因20号外显子插入突变中对莫博赛替尼获得性耐药的继发性突变
约10%的非小细胞肺癌EGFR突变为20号外显子插入(X20ins),对常规EGFR酪氨酸激酶抑制剂(TKI)不敏感。本研究通过体外慢性暴露于莫博赛替尼的小鼠pro-B细胞系模型,发现不同X20ins亚型产生不同的继发性耐药突变:insFQEA和insSVD仅出现C797S,而insASV、insNPH和insH则出现T790M或C797S。舒沃替尼对T790M耐药细胞有良好活性,可能成为T790M介导耐药患者的治疗选择。
要点
- X20ins不同亚型的莫博赛替尼获得性耐药机制不同:insFQEA和insSVD仅出现C797S,insASV、insNPH和insH出现T790M或C797S。
- 低浓度药物处理更易出现T790M耐药突变。
- 舒沃替尼对T790M耐药细胞有良好活性;C797S耐药细胞对所有EGFR TKI难治,仅厄洛替尼对insFQEA伴C797S有活性。
核心结论
- 取决于原始X20ins突变类型,T790M或C797S介导对莫博赛替尼的获得性耐药。
- 舒沃替尼可能成为因T790M导致莫博赛替尼耐药患者的治疗选择。
研究设计与样本
- 体外研究:将转导五种最常见X20ins(A763_Y764insFQEA、V769_D770insASV、D770_N771insSVD、H773_V774insNPH和H773_V774insH)的小鼠pro-B细胞系在N-乙基-N-亚硝基脲存在下长期暴露于莫博赛替尼,寻找继发性EGFR突变。
- 评估多种EGFR X20ins抑制剂(包括zipalertinib和舒沃替尼)对获得性耐药细胞的活性。
主要发现
- insFQEA和insSVD的所有继发性耐药突变均为C797S。
- insASV、insNPH和insH中,T790M或C797S继发性突变均参与对莫博赛替尼的获得性耐药。
- 较低药物浓度处理的细胞中T790M出现更频繁。
- 舒沃替尼对携带T790M的耐药细胞表现出良好活性。
- 携带C797S的细胞对所有EGFR TKI难治,但厄洛替尼对insFQEA伴C797S有活性。
关键数值与推荐
- 约10%的NSCLC EGFR基因突变为20号外显子框内插入(X20ins)。
- 莫博赛替尼近期获美国食品药品监督管理局批准。
- 五种最常见X20ins:A763_Y764insFQEA、V769_D770insASV、D770_N771insSVD、H773_V774insNPH和H773_V774insH。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Approximately 10% of mutations in the EGFR gene in NSCLC are in-frame insertions in exon 20 (X20ins). These tumors usually do not respond to conventional EGFR tyrosine kinase inhibitors (TKIs). Several novel EGFR TKIs active for X20ins are in clinical development, including mobocertinib, which was recently approved by the U.S. Food and Drug Administration. However, acquired resistance during treatment with these TKIs still occurs as in the case of EGFR TKIs of earlier generations. METHODS: We chronically exposed murine pro-B-cell line cells transduced with the five most common X20ins (A763_Y764insFQEA, V769_D770insASV, D770_N771insSVD, H773_V774insNPH and H773_V774insH) to mobocertinib in the presence of N-ethyl-N-nitrosourea and searched for secondary EGFR mutations. We evaluated the efficacies of several EGFR X20ins inhibitors, including zipalertinib and sunvozertinib, against cells with acquired resistant mutations. RESULTS: All secondary mutations resulting in acquired resistance to mobocertinib were exclusively C797S in insFQEA and insSVD. However, in the case of other X20ins (insASV, insNPH, and insH), T790M or C797S secondary mutations contributed to acquired resistance to mobocertinib. The emergence of T790M was more frequent in cells treated with lower drug concentrations. Sunvozertinib exhibited good activity against resistant cells with T790M. Cells with C797S were refractory to all EGFR TKIs, except for erlotinib, which was active for insFQEA with C797S. CONCLUSIONS: T790M or C797S, depending on the original X20ins mutations, conferred acquired resistance to mobocertinib. Sunvozertinib may be the treatment of choice for patients with tumors resistant to mobocertinib because of T790M.
引用
- Hamada A, Suda K, Nishino M, et al. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. J Thorac Oncol. 2023. PMID: 37666482. doi:10.1016/j.jtho.2023.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。